IRF8-mutant B cell lymphoma evades immunity through a CD74-dependent deregulation of antigen processing and presentation in MHCII complexes.
Zhijun QiuJihane KhalifePurushoth EthirajCarine JaafarAn-Ping LinKenneth N HolderJacob P RitterLilly ChiouGabriela Huelgas-MoralesSadia AslamZhao ZhangZhijie LiuShailee AryaYogesh K GuptaPatricia L M DahiaRicardo C T AguiarPublished in: Science advances (2024)
The mechanism by which interferon regulatory factor 8 (IRF8) mutation contributes to lymphomagenesis is unknown. We modeled IRF8 variants in B cell lymphomas and found that they affected the expression of regulators of antigen presentation. Expression of IRF8 mutants in murine B cell lymphomas suppressed CD4, but not CD8, activation elicited by antigen presentation and downmodulated CD74 and human leukocyte antigen (HLA) DM, intracellular regulators of antigen peptide processing/loading in the major histocompatibility complex (MHC) II. Concordantly, mutant IRF8 bound less efficiently to the promoters of these genes. Mice harboring IRF8 mutant lymphomas displayed higher tumor burden and remodeling of the tumor microenvironment, typified by depletion of CD4, CD8, and natural killer cells, increase in regulatory T cells and T follicular helper cells. Deconvolution of bulk RNA sequencing data from IRF8-mutant human diffuse large B cell lymphoma (DLBCL) recapitulated part of the immune remodeling detected in mice. We concluded that IRF8 mutations contribute to DLBCL biology by facilitating immune escape.
Keyphrases
- dendritic cells
- diffuse large b cell lymphoma
- regulatory t cells
- wild type
- endothelial cells
- poor prognosis
- immune response
- epstein barr virus
- transcription factor
- natural killer cells
- type diabetes
- oxidative stress
- induced apoptosis
- adipose tissue
- gene expression
- machine learning
- genome wide
- long non coding rna
- cell cycle arrest
- insulin resistance
- skeletal muscle
- big data
- dna methylation
- induced pluripotent stem cells
- electronic health record
- risk factors
- pluripotent stem cells
- glycemic control